20% of participants had 80% reduction in AHI. the average was 44% reduction in AHI across the spectrum. Pre meeting arranged with FDA.
- Forums
- ASX - By Stock
- Ann: IHL-42X positive phase 2 clinical trial results
20% of participants had 80% reduction in AHI. the average was...
-
-
- There are more pages in this discussion • 369 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online